Objective To observe the effect of elemene oral breast combined with docetaxel+oxaliplatin (DO) chemotherapy regimen on serum levels of miR-203 and miR-21 in patients with advanced esophageal cancer. Methods A total of 92 patients with advanced esophageal cancer who were treated in Nanyang Zhang Zhongjing Hospital from January 2017 to February 2019 were selected and divided into two groups according to the random number table method, with 46 cases in each group. The routine group was treated with DO, chemotherapy regimen and the study group was treated with elemene oral breast on the basis of the routine group. The objective response rate (ORR), disease control rate (DCR), immune function, serum tumor markers, serum levels of miR-203, miR-21 and changes of long-term survival were compared between the two groups. Results The ORR of the study group was 60.86%, which was higher than that of the routine group (39.13%, P<0.05); the DCR of the study group was 76.09%, which was higher than that of the routine group (56.52%, P<0.05). After treatment, the levels of NK and CD4 ⁺ in the study group were higher than those in the routine group, the level of CD8 ⁺ was lower than that in the routine group ( P<0.05). After treatment, the CEA, SCC, TSGF, NSE indexes in the study group were lower than those in the routine group ( P<0.05). After treatment,the level of miR-21 in the study group was higher than that in the routine group, and the level of miR-21 was lower than that in the routine group ( P<0.05). The two-year follow-up showed that the 1-year survival rate and the 2-year survival rate of the study group were higher than those of the routine group ( P<0.05). Conclusion Elemene oral breast combined with DO chemotherapy regimen in treatment of advanced esophageal cancer can effectively regulate the immune function of patients and the expression of miR-203 and miR-21, and prolong the survival period with significant effect.

Objective To analyze the effect of tiotropium bromide on patients with chronic obstructive pulmonary disease (COPD) and the influence on peripheral blood EOS, IL-25 and IL-35. Methods A total of 186 patients with chronic obstructive pulmonary disease admitted from January 2018 to December 2019 were randomly divided into observation group and control group (93 patients each). On the basis of routine treatment were given to the patients in 2 groups, the control group was given salbutamol sulfate inhalation, while the observation group was given tiotropium bromide inhalation. Clinical symptoms, lung function test results and adverse reactions of the two groups were recorded, and EOS and IL-25, IL-35 were detected by Automatic blood routine analyzer and ELISA respectively. Results Compared with before treatment, the clinical curative effect and the pulmonary function index were significantly improved after treatment in the two groups. Compared with the control group, the clinical curative effect and the pulmonary function index of the observation group were improved more significantly, the incidence of palpitation decreased significantly (P<0.05), the levels of EOS and IL-25 in peripheral blood were decreased, while the levels of IL-35 were increased, showing statistical differences (P<0.05). Conclusion In patients with COPD, Tiotropium Bromide spray inhalation treatment has significant clinical effect and good safety, and regulating the expression levels of EOS, IL-25 and IL-35 in peripheral blood may play a role in its efficacy, which is worthy of clinical promotion and application.